MX2020005046A - Inhibidores de inmunoproteasoma. - Google Patents
Inhibidores de inmunoproteasoma.Info
- Publication number
- MX2020005046A MX2020005046A MX2020005046A MX2020005046A MX2020005046A MX 2020005046 A MX2020005046 A MX 2020005046A MX 2020005046 A MX2020005046 A MX 2020005046A MX 2020005046 A MX2020005046 A MX 2020005046A MX 2020005046 A MX2020005046 A MX 2020005046A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- immunoproteasome
- inhibitors
- immunoproteasome inhibitors
- immunoproteasomes
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente descripción se proporcionan compuestos, tales como un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable de este, que son inhibidores de inmunoproteasoma (tales como LMP2 y LMP7). Los compuestos descritos en la presente descripción pueden ser útiles para el tratamiento de enfermedades tratables mediante la inhibición de inmunoproteasomas. En la presente descripción también se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587376P | 2017-11-16 | 2017-11-16 | |
| PCT/US2018/061140 WO2019099582A1 (en) | 2017-11-16 | 2018-11-14 | Immunoproteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005046A true MX2020005046A (es) | 2020-08-20 |
Family
ID=64746633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005046A MX2020005046A (es) | 2017-11-16 | 2018-11-14 | Inhibidores de inmunoproteasoma. |
| MX2022012825A MX2022012825A (es) | 2017-11-16 | 2020-07-13 | Inhibidores de inmunoproteasoma. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012825A MX2022012825A (es) | 2017-11-16 | 2020-07-13 | Inhibidores de inmunoproteasoma. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11225493B2 (es) |
| EP (1) | EP3710458A1 (es) |
| JP (1) | JP7277457B2 (es) |
| KR (1) | KR102625984B1 (es) |
| CN (1) | CN111491938A (es) |
| AU (1) | AU2018367515B2 (es) |
| CA (1) | CA3080949C (es) |
| CL (1) | CL2020001244A1 (es) |
| CO (1) | CO2020007150A2 (es) |
| EA (1) | EA202090900A1 (es) |
| IL (1) | IL274523B2 (es) |
| MA (1) | MA50906A (es) |
| MX (2) | MX2020005046A (es) |
| NZ (1) | NZ764393A (es) |
| PH (1) | PH12020550580A1 (es) |
| SG (1) | SG11202003867SA (es) |
| WO (1) | WO2019099582A1 (es) |
| ZA (1) | ZA202002531B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3571208T1 (sl) * | 2017-01-18 | 2021-06-30 | Principia Biopharma Inc. | Zaviralci imunoproteasomov |
| WO2019099582A1 (en) | 2017-11-16 | 2019-05-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| WO2024006337A1 (en) * | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Cyclic boronic esters and their uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4963655A (en) | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| KR101292707B1 (ko) | 2004-02-23 | 2013-08-02 | 트러스티즈 오브 터프츠 칼리지 | 디펩티딜펩티다아제 ⅳ의 억제제 |
| JP6042724B2 (ja) * | 2010-03-01 | 2016-12-14 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | イムノプロテアソーム阻害のための化合物 |
| WO2013092979A1 (en) | 2011-12-22 | 2013-06-27 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| US10654843B2 (en) | 2014-06-20 | 2020-05-19 | Principia Biopharma Inc. | LMP7 inhibitors |
| AU2015327345B9 (en) * | 2014-10-01 | 2020-06-18 | Merck Patent Gmbh | Boronic acid derivatives |
| CN106588965A (zh) * | 2015-10-15 | 2017-04-26 | 北京大学 | 脲拟肽硼酸化合物及其药物组合物、制备方法和用途 |
| SI3571208T1 (sl) | 2017-01-18 | 2021-06-30 | Principia Biopharma Inc. | Zaviralci imunoproteasomov |
| WO2019099582A1 (en) | 2017-11-16 | 2019-05-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| US20230133165A1 (en) | 2017-11-16 | 2023-05-04 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
-
2018
- 2018-11-14 WO PCT/US2018/061140 patent/WO2019099582A1/en unknown
- 2018-11-14 CN CN201880074665.3A patent/CN111491938A/zh active Pending
- 2018-11-14 EA EA202090900A patent/EA202090900A1/ru unknown
- 2018-11-14 KR KR1020207017251A patent/KR102625984B1/ko active IP Right Grant
- 2018-11-14 MX MX2020005046A patent/MX2020005046A/es unknown
- 2018-11-14 US US16/764,136 patent/US11225493B2/en active Active
- 2018-11-14 NZ NZ764393A patent/NZ764393A/en unknown
- 2018-11-14 MA MA050906A patent/MA50906A/fr unknown
- 2018-11-14 SG SG11202003867SA patent/SG11202003867SA/en unknown
- 2018-11-14 IL IL274523A patent/IL274523B2/en unknown
- 2018-11-14 JP JP2020527042A patent/JP7277457B2/ja active Active
- 2018-11-14 AU AU2018367515A patent/AU2018367515B2/en active Active
- 2018-11-14 EP EP18822543.7A patent/EP3710458A1/en active Pending
- 2018-11-14 CA CA3080949A patent/CA3080949C/en active Active
-
2020
- 2020-05-07 PH PH12020550580A patent/PH12020550580A1/en unknown
- 2020-05-07 ZA ZA2020/02531A patent/ZA202002531B/en unknown
- 2020-05-12 CL CL2020001244A patent/CL2020001244A1/es unknown
- 2020-06-11 CO CONC2020/0007150A patent/CO2020007150A2/es unknown
- 2020-07-13 MX MX2022012825A patent/MX2022012825A/es unknown
-
2021
- 2021-11-16 US US17/527,514 patent/US11827656B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL274523B1 (en) | 2023-10-01 |
| IL274523B2 (en) | 2024-02-01 |
| US11827656B2 (en) | 2023-11-28 |
| WO2019099582A1 (en) | 2019-05-23 |
| US20220073538A1 (en) | 2022-03-10 |
| SG11202003867SA (en) | 2020-05-28 |
| KR102625984B1 (ko) | 2024-01-18 |
| JP7277457B2 (ja) | 2023-05-19 |
| PH12020550580A1 (en) | 2021-04-26 |
| KR20200085868A (ko) | 2020-07-15 |
| CN111491938A (zh) | 2020-08-04 |
| AU2018367515B2 (en) | 2023-04-27 |
| US20200277312A1 (en) | 2020-09-03 |
| MA50906A (fr) | 2020-09-23 |
| JP2021503471A (ja) | 2021-02-12 |
| EA202090900A1 (ru) | 2020-10-02 |
| CL2020001244A1 (es) | 2020-08-21 |
| CA3080949A1 (en) | 2019-05-23 |
| BR112020009516A2 (pt) | 2020-11-03 |
| IL274523A (en) | 2020-06-30 |
| NZ764393A (en) | 2023-11-24 |
| MX2022012825A (es) | 2022-11-07 |
| AU2018367515A1 (en) | 2020-05-14 |
| EP3710458A1 (en) | 2020-09-23 |
| CO2020007150A2 (es) | 2020-06-19 |
| CA3080949C (en) | 2024-04-16 |
| ZA202002531B (en) | 2023-10-25 |
| US11225493B2 (en) | 2022-01-18 |
| TW201930264A (zh) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY200608A (en) | Hiv inhibitor compounds | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| PH12020550256A1 (en) | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
| SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
| AU2018231032A8 (en) | JAK inhibitors containing a 4-membered heterocyclic amide | |
| EA201890473A1 (ru) | Гетероарильные производные в качестве ингибиторов parp | |
| MX2022012825A (es) | Inhibidores de inmunoproteasoma. | |
| MX2019008436A (es) | Inhibidores del inmunoproteasoma. | |
| PH12020551013A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
| WO2015195950A8 (en) | Lmp7 inhibitors | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| MX2020005036A (es) | Inhibidores de inmunoproteasoma. | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| NZ727715A (en) | Novel heterocyclic compounds having prs enzyme inhibitory effect | |
| MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
| NZ735249A (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease |